|Home / Advance Research / For Industry and Investors|
For Industry and Investors
The average new drug today costs over $1 billion to develop and takes more than 10 years – that’s one billion dollars the Duchenne community doesn’t have and ten years we can’t spare. But it’s a problem that can and must be solved with a carefully evolved plan. PPMD’s Global Investment For Therapeutics to End Duchenne (GIFTED) is a fund that invests in three types of projects:
In each case, PPMD sets specific qualitative and quantitative goals that will be measured and reported to the Duchenne community. Explore these pages to learn more about the business strategy behind GIFTED and the Duchenne Report Card, which describes the status of infrastructure (tools, techniques, and services) needed to develop new therapies.
In this section